Not all breast cancers are the same. Breast cancer is heterogeneous in nature, which means that different breast cancers can behave differently, grow at different speeds, respond differently to treatment, and carry different risks of recurrence.
This is why a breast cancer diagnosis is not complete with the word cancer alone. Once cancer is diagnosed on biopsy, the next important question is: what type of breast cancer is it?
Knowing the type helps the treating team plan treatment more precisely. It helps decide whether a patient may need hormone therapy, chemotherapy, HER2-targeted therapy, immunotherapy, or a combination of treatments. The aim is to tailor treatment to the biology of the cancer and the individual patient, rather than using one standard plan for everyone.
Why Breast Cancer Type Matters
Breast cancers are categorized based on their likely behaviour and the markers present on cancer cells. These markers help doctors understand how the cancer may grow, how aggressive it may be, and which treatments are most likely to work.
Two patients may have breast cancer of a similar size or stage, but their treatment plans may still be different if the tumour biology is different. This is because treatment is planned not only according to where the cancer is, but also according to how the cancer behaves.
How The Type Is Identified
The type of breast cancer is usually identified by testing the biopsy tissue. The same tissue sample that confirms the diagnosis can also provide important information about the biology of the cancer.
Commonly tested markers include estrogen receptor, or ER, progesterone receptor, or PR, and HER2. These are often called receptor tests or biomarker tests. Ki-67 may also be assessed in some reports, as it gives information about how actively the cancer cells are dividing.
In selected situations, additional genomic or molecular tests may be advised. These are not required for every patient, but they may help refine treatment decisions in certain early-stage hormone receptor-positive cancers or in selected advanced cancers.
This is why biopsy is important not only for confirming cancer, but also for planning treatment.
Hormone Receptor-Positive Breast Cancer
Hormone receptor-positive breast cancers have estrogen receptors, progesterone receptors, or both. These cancers may depend on hormones such as estrogen or progesterone to grow.
This type is often less aggressive than some other biological subtypes, especially when it is detected early and has favourable features. A major advantage is that hormone therapy can be used to reduce the effect of hormones on cancer cells.
Treatment may include surgery, radiation, hormone therapy, and sometimes chemotherapy, depending on stage, grade, lymph node involvement, patient age, menopausal status, and other risk factors.
In some patients, hormone receptor-positive breast cancer may require less toxic treatment than more aggressive subtypes. However, this decision should always be individualized. Not every hormone receptor-positive cancer is low-risk, and not every patient can avoid chemotherapy.
HER2-Positive Breast Cancer
HER2-positive breast cancers have higher levels of a protein called HER2, which can make cancer cells grow and divide more quickly. These cancers were historically considered more aggressive.
However, treatment for HER2-positive breast cancer has changed significantly because HER2-targeted therapies are now available. These medicines specifically target the HER2 pathway and can improve treatment outcomes when used appropriately.
HER2-positive breast cancer often requires more intensive treatment planning. Depending on the stage and clinical situation, treatment may include chemotherapy along with HER2-targeted therapy, and sometimes hormone therapy if the cancer is also hormone receptor-positive.
Knowing HER2 status is therefore essential. Without this information, the treatment plan may miss an important target.
Triple-Negative Breast Cancer
Triple-negative breast cancer means that the cancer cells do not have estrogen receptors, progesterone receptors, or excess HER2 expression. This means that hormone therapy and HER2-targeted therapy are not useful for this subtype.
Triple-negative breast cancer can be more aggressive and may grow or spread faster than some other types. It also often requires more intensive treatment, commonly involving chemotherapy. In selected patients, immunotherapy or other targeted approaches may also be considered depending on stage, biomarkers, genetic factors, and treatment setting.
This does not mean that triple-negative breast cancer cannot be treated. It means that the treatment pathway is different, and timely, well-planned treatment becomes especially important.
Why The Same Diagnosis Can Lead To Different Treatment Plans
A common source of confusion is that two people may both be diagnosed with breast cancer but receive different treatments. One patient may need hormone tablets for several years, another may need chemotherapy and HER2-targeted therapy, while another may need chemotherapy before surgery.
This difference does not mean that one patient is being treated more or less seriously. It means that treatment is being matched to the cancer type, stage, patient factors, and treatment goals.
The same stage of breast cancer may require different treatment depending on tumour biology. This is why pathology and biomarker reports are central to treatment planning.
A Key Point To Remember
The biopsy does not only confirm whether cancer is present. It also helps identify the type of breast cancer and provides information that guides treatment.
A Measured Approach
Understanding the type of breast cancer helps avoid both under-treatment and over-treatment. Less aggressive cancers may not always need the most intense treatment, while more aggressive subtypes may need stronger and more carefully sequenced treatment.
Breast cancer treatment should be personalized, evidence-based, and guided by the information obtained from biopsy, receptor testing, imaging, stage, and overall patient health.
